Haploinsuficient NHERF1 tumor suppressor activity would also explain the relatively low frequency of intragenic mutations, although the possibility that other NHERF1 pathway components are genetically altered cannot be ruled out. The gene discussed is NHERF1; the disease is neoplasm.